Drug Interaction Report

The vadadustat in Vafseo has a moderate potential interaction with Alcoholism.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

Suprofen ophthalmic has a major potential interaction with Asthma.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients. A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs. Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity. NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.

The vadadustat in Vafseo has a moderate potential interaction with Bladder Cancer.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

Suprofen ophthalmic has a moderate potential interaction with Bleeding Disorder.

Topically applied nonsteroidal anti-inflammatory drugs (NSAIDs) are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. NSAIDs have been shown to reversibly inhibit platelet adhesion and aggregation and may slightly prolong bleeding time in healthy individuals. These effects may be more pronounced in patients with underlying hemostatic abnormalities. Thrombocytopenia has also been reported rarely during NSAID use. Therapy with ocular NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.

The vadadustat in Vafseo has a moderate potential interaction with Breast Cancer.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

The vadadustat in Vafseo has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Vadadustat increases the risk of arterial and venous thrombotic events, including major adverse cardiovascular events. Patients with cardiovascular or cerebrovascular disease are at increased risk. Avoid the use of this drug in patients with history of myocardial infarction, cerebrovascular events, or acute coronary syndrome within the 3 months prior to starting treatment.

Suprofen ophthalmic has a moderate potential interaction with Coagulation Defects and Disorders.

Topically applied nonsteroidal anti-inflammatory drugs (NSAIDs) are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. NSAIDs have been shown to reversibly inhibit platelet adhesion and aggregation and may slightly prolong bleeding time in healthy individuals. These effects may be more pronounced in patients with underlying hemostatic abnormalities. Thrombocytopenia has also been reported rarely during NSAID use. Therapy with ocular NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.

The vadadustat in Vafseo has a moderate potential interaction with Esophageal Disease.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

The vadadustat in Vafseo has a moderate potential interaction with Gastrointestinal Hemorrhage.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

The vadadustat in Vafseo has a major potential interaction with High Blood Pressure.

Vadadustat is contraindicated in patients with uncontrolled hypertension as cases of hypertensive crisis including hypertensive encephalopathy and seizures have been reported. Patients with history of seizure disorders receiving this drug should be monitored closely and should contact their health care provider for premonitory symptoms or change in seizure frequency.

The vadadustat in Vafseo has a moderate potential interaction with Liver Disease.

Vadadustat may cause hepatotoxicity. Liver enzymes and bilirubin should be measured prior to treatment initiation and monitored during treatment. This drug is not recommended in patients with cirrhosis, or active, acute liver disease.

The vadadustat in Vafseo has a moderate potential interaction with Lung Cancer.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

The vadadustat in Vafseo has a moderate potential interaction with Prostate Cancer.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

The vadadustat in Vafseo has a major potential interaction with Seizures.

Vadadustat is contraindicated in patients with uncontrolled hypertension as cases of hypertensive crisis including hypertensive encephalopathy and seizures have been reported. Patients with history of seizure disorders receiving this drug should be monitored closely and should contact their health care provider for premonitory symptoms or change in seizure frequency.

The vadadustat in Vafseo has a moderate potential interaction with Skin Cancer.

An increase in hypoxia inducible factor (HIF) levels may be associated with unfavorable effects on cancer growth. The use of vadadustat has not been studied and is not recommended in patients with active malignancies.

The vadadustat in Vafseo has a moderate potential interaction with Smoking.

Esophageal and gastrointestinal erosions have been reported with the use of vadadustat. Some cases of serious gastrointestinal bleeding required the need for red blood cell transfusions. Patients with history of gastrointestinal erosion, peptic ulcer disease, tobacco smokers and alcohol drinkers are at increased risk.

Suprofen ophthalmic has a moderate potential interaction with Thrombocytopathy.

Topically applied nonsteroidal anti-inflammatory drugs (NSAIDs) are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. NSAIDs have been shown to reversibly inhibit platelet adhesion and aggregation and may slightly prolong bleeding time in healthy individuals. These effects may be more pronounced in patients with underlying hemostatic abnormalities. Thrombocytopenia has also been reported rarely during NSAID use. Therapy with ocular NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.

Suprofen ophthalmic has a moderate potential interaction with Thrombocytopenia.

Topically applied nonsteroidal anti-inflammatory drugs (NSAIDs) are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. NSAIDs have been shown to reversibly inhibit platelet adhesion and aggregation and may slightly prolong bleeding time in healthy individuals. These effects may be more pronounced in patients with underlying hemostatic abnormalities. Thrombocytopenia has also been reported rarely during NSAID use. Therapy with ocular NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.

Suprofen ophthalmic has a moderate potential interaction with Vitamin K Deficiency.

Topically applied nonsteroidal anti-inflammatory drugs (NSAIDs) are systemically absorbed, with the potential for producing rare but clinically significant systemic effects. NSAIDs have been shown to reversibly inhibit platelet adhesion and aggregation and may slightly prolong bleeding time in healthy individuals. These effects may be more pronounced in patients with underlying hemostatic abnormalities. Thrombocytopenia has also been reported rarely during NSAID use. Therapy with ocular NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.